Thrivent Financial for Lutherans Acquires 79,636 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU)

Thrivent Financial for Lutherans raised its stake in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) by 74.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 186,621 shares of the company’s stock after buying an additional 79,636 shares during the quarter. Thrivent Financial for Lutherans owned about 0.21% of Caribou Biosciences worth $297,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of the stock. Geode Capital Management LLC grew its stake in Caribou Biosciences by 6.5% during the third quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock valued at $3,980,000 after acquiring an additional 124,782 shares in the last quarter. US Bancorp DE grew its position in shares of Caribou Biosciences by 3,524.2% during the fourth quarter. US Bancorp DE now owns 27,218 shares of the company’s stock valued at $43,000 after purchasing an additional 26,467 shares in the last quarter. Barclays PLC increased its holdings in shares of Caribou Biosciences by 122.4% in the third quarter. Barclays PLC now owns 129,839 shares of the company’s stock worth $255,000 after purchasing an additional 71,463 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Caribou Biosciences by 19.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 739,530 shares of the company’s stock worth $1,449,000 after buying an additional 118,325 shares in the last quarter. Finally, FMR LLC boosted its stake in Caribou Biosciences by 7.4% during the third quarter. FMR LLC now owns 1,581,493 shares of the company’s stock valued at $3,100,000 after buying an additional 109,606 shares during the last quarter. Hedge funds and other institutional investors own 77.51% of the company’s stock.

Analyst Ratings Changes

CRBU has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Caribou Biosciences in a research note on Wednesday, March 19th. Bank of America cut their target price on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $10.33.

Caribou Biosciences Price Performance

Shares of NASDAQ CRBU opened at $0.77 on Friday. The stock has a market capitalization of $71.38 million, a P/E ratio of -0.47 and a beta of 2.34. Caribou Biosciences, Inc. has a 1-year low of $0.70 and a 1-year high of $4.67. The business’s 50 day moving average is $1.17 and its two-hundred day moving average is $1.67.

Caribou Biosciences (NASDAQ:CRBU) last released its quarterly earnings results on Monday, March 10th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.01. The company had revenue of $2.08 million for the quarter, compared to analyst estimates of $2.11 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. As a group, equities research analysts anticipate that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current fiscal year.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.